Table of Content

1. Key Insights

2. Executive Summary of Bipolar Depression

3. Bipolar Depression Market Overview at a Glance
3.1. Market Share (%) Distribution of Bipolar Depression in 2017
3.2. Market Share (%) Distribution of Bipolar Depression in 2030

4. Disease Background and Overview: Bipolar Depression
4.1. Introduction
4.2. Classification of Bipolar Disorder According to DSM-5
4.3. Symptoms
4.4. Causes
4.5. Risk Factors
4.6. Pathophysiology
4.7. Genetics Findings in Bipolar Disorder
4.8. Biomarkers
4.9. Diagnosis
4.9.1. Diagnostic Guidelines

5. Case Reports
5.1. Bipolar II Disorder: Case Study
5.2. Clinical Characteristics and Legal Consequences of Violent Behavior: A Case of Bipolar Disorder
5.3. Effectiveness of Simple Individual Psychoeducation for Bipolar II Disorder

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. KOL Views
6.3. Epidemiology Methodology
6.4. Total Diagnosed Prevalent Cases of Bipolar Depression in the 7MM

7. United States Epidemiology
7.1. Assumptions and Rationale
7.2. Total Diagnosed Prevalent Cases of Bipolar Depression in the United States
7.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the United States
7.4. Severity-specific Diagnosed Prevalent cases of Bipolar Depression in the United States

8. EU5 Epidemiology
8.1. Germany Epidemiology
8.1.1. Assumptions and Rationale
8.1.2. Total Diagnosed Prevalent Cases of Bipolar Depression in Germany
8.1.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany
8.1.4. Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany
8.2. France Epidemiology
8.2.1. Assumptions and Rationale
8.2.2. Total Diagnosed Prevalent Cases of Bipolar Depression in France
8.2.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in France
8.2.4. Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in France
8.3. Italy Epidemiology
8.3.1. Assumptions and Rationale
8.3.2. Total Diagnosed Prevalent Cases of Bipolar Depression in Italy
8.3.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy
8.3.4. Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy
8.4. Spain Epidemiology
8.4.1. Assumptions and Rationale
8.4.2. Total Diagnosed Prevalent Cases of Bipolar Depression in Spain
8.4.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain
8.4.4. Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain
8.5. United Kingdom Epidemiology
8.5.1. Assumptions and Rationale
8.5.2. Total Diagnosed Prevalent Cases of Bipolar Depression in the UK
8.5.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK
8.5.4. Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK

9. Japan Epidemiology
9.1. Assumptions and Rationale
9.2. Total Diagnosed Prevalent Cases of Bipolar Depression in Japan
9.3. Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Japan
9.4. Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Japan

10. Current Treatment and Medical Practices
10.1. Treatment of Bipolar Disorder
10.1.1. Treatment Algorithm
10.1.2. Treatment Guideline

11. Unmet needs

12. Marketed Drugs
12.1. Vraylar (Cariprazine): Allergan (AbbVie)/Gedeon Richter
12.1.1. Product Description
12.1.2. Regulatory Milestones
12.1.3. Other Development Activities
12.1.4. Clinical Development
12.1.5. Safety and Efficacy
12.1.6. Product Profile
12.2. Latuda (Lurasidone Hydrochloride): Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)
12.2.1. Product Description
12.2.2. Regulatory Milestones
12.2.3. Other Development Activities
12.2.4. Clinical Development
12.2.5. Safety and Efficacy
12.2.6. Product Profile

13. Emerging Drugs
13.1. Key Cross Competition
13.2. Abilify (Aripiprazole): Otsuka Pharmaceutical
13.2.1. Product Description
13.2.2. Other Developmental Activities
13.2.3. Clinical Development
13.2.4. Safety and Efficacy
13.2.5. Product Profile
13.3. Lumateperone/ITI-007: Intra-cellular Therapies
13.3.1. Product Description
13.3.2. Other Developmental Activities
13.3.3. Clinical Development
13.3.4. Product Profile
13.4. NRX-100/NRX-101: NeuroRx
13.4.1. Product Description
13.4.2. Other Developmental Activities
13.4.3. Clinical Development
13.4.4. Product Profile
13.5. Psilocybin: COMPASS Pathways
13.5.1. Product Description
13.5.2. Other Developmental Activities
13.5.3. Clinical Development
13.5.4. Product Profile
13.6. Zuranolone (SAGE-217): Sage Therapeutics
13.6.1. Product Description
13.6.2. Other Developmental Activities
13.6.3. Clinical Development
13.6.4. Product Profile
13.7. SEP-4199: Sunovion/Sumitomo Dainippon Pharma
13.7.1. Product Description
13.7.2. Other Developmental Activities
13.7.3. Clinical Development
13.7.4. Product Profile
13.8. ILT101: Iltoo Pharma
13.8.1. Product Description
13.8.2. Clinical Development
13.8.3. Product Profile
13.9. Falkieri (Esketamine DPI): Celon Pharma
13.9.1. Product Description
13.9.2. Other Developmental Activities
13.9.3. Clinical Development
13.9.4. Product Profile

14. Bipolar Depression: 7MM Market Analysis
14.1. Key Findings
14.2. Market Methodology
14.3. Attribute Analysis
14.4. Key Market Forecast Assumptions
14.5. Market Size of Bipolar Depression in the 7MM
14.6. Market Size of Bipolar Depression by Therapies in the 7MM

15. United States Market Outlook
15.1. United States Market Size
15.1.1. Total market size of Bipolar Depression in the United States
15.1.2. Market Size of Bipolar Depression by Therapies in the US

16. EU-5 Market Outlook
16.1. Germany Market Size
16.1.1. Total Market size of Bipolar Depression in Germany
16.1.2. Market Size of Bipolar Depression by therapies in Germany
16.2. France Market Size
16.2.1. Total Market size of Bipolar Depression in France
16.2.2. Market Size of Bipolar Depression by therapies in France
16.3. Italy Market Size
16.3.1. Total Market size of Bipolar Depression in Italy
16.3.2. Market Size of Bipolar Depression by therapies in Italy
16.4. Spain Market Size
16.4.1. Total Market size of Bipolar Depression in Spain
16.4.2. Market Size of Bipolar Depression by therapies in Spain
16.5. United Kingdom Market Size
16.5.1. Total Market size of Bipolar Depression in the United Kingdom
16.5.2. Market Size of Bipolar Depression by therapies in the UK
17. Japan Market Outlook
17.1. Japan Market Size
17.1.1. Total Market size of Bipolar Depression in Japan
17.1.2. Market Size of Bipolar Depression by therapies in Japan
18. Market Drivers
19. Market Barriers
20. SWOT Analysis
21. Reimbursement and Market Access
22. Appendix
22.1. Bibliography
22.2. Report Methodology
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight



List of Figures


Figure 1 Main subtypes of bipolar disorder
Figure 2 Symptoms of bipolar disorder
Figure 3 Effects of bipolar disorder on the body
Figure 4 Causes of bipolar disorder
Figure 5 Triggers in bipolar disorder
Figure 6 Multifactorial model of bipolar disorders
Figure 7 Symptoms with potential diagnostic utility in bipolar and unipolar depression
Figure 8 United States KOL Views
Figure 9 EU-5 and Japan KOL Views
Figure 10 Total Diagnosed Prevalent Cases of Bipolar Depression in the 7MM (2017–2030)
Figure 11 Total Diagnosed Prevalent Cases of Bipolar Depression in the United States (2017–2030)
Figure 12 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the United States (2017–2030)
Figure 13 Severity-specific Diagnosed Prevalent cases of Bipolar Depression in the US (2017–2030)
Figure 14 Total Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)
Figure 15 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)
Figure 16 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)
Figure 17 Total Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)
Figure 18 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)
Figure 19 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)
Figure 20 Total Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)
Figure 21 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)
Figure 22 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)
Figure 23 Total Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)
Figure 24 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)
Figure 25 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)
Figure 26 Total Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)
Figure 27 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)
Figure 28 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)
Figure 29 Total Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)
Figure 30 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)
Figure 31 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)
Figure 32 Algorithm for the Treatment of Mania/Hypomania
Figure 33 Algorithm for the Treatment of Depression in Bipolar Disorder*
Figure 34 Unmet needs
Figure 35 Market Size of Bipolar Depression in the 7MM in USD Million (2017–2030)
Figure 36 Market Size of Bipolar Depression by therapies in the 7MM, in USD Million (2017–2030)
Figure 37 Market Size of Bipolar Depression in the US, USD Millions (2017–2030)
Figure 38 Market Size of Bipolar Depression by therapies in the US, in USD Million (2017–2030)
Figure 39 Market Size of Bipolar Depression in Germany, USD Millions (2017–2030)
Figure 40 Market Size of Bipolar Depression by therapies in Germany, in USD Million (2017–2030)
Figure 41 Market Size of Bipolar Depression in France, USD Millions (2017–2030)
Figure 42 Market Size of Bipolar Depression by therapies in France, in USD Million (2017–2030)
Figure 43 Market Size of Bipolar Depression in Italy, USD Millions (2017–2030)
Figure 44 Market Size of Bipolar Depression by therapies in Italy in USD Million (2017–2030)
Figure 45 Market Size of Bipolar Depression in Spain, USD Millions (2017–2030)
Figure 46 Market Size of Bipolar Depression by therapies in Spain in USD Million (2017–2030)
Figure 47 Market Size of Bipolar Depression in the UK, USD Millions (2017–2030)
Figure 48 Market Size of Bipolar Depression by therapies in the UK in USD Million (2017–2030)
Figure 49 Market Size of Bipolar Depression in Japan, USD Millions (2017–2030)
Figure 50 Market Size of Bipolar Depression by therapies in Japan in USD Million (2017–2030)
Figure 51 Market Drivers
Figure 52 Market Barriers
Figure 53 SWOT analysis

 

List of Tables


Table 1 Summary of Bipolar Depression, Market, Epidemiology and Key Events (2017–2030)
Table 2 Symptoms associated with manic and depressive episodes
Table 3 GWAS findings in bipolar disorder
Table 4 Main findings of circulating biomarkers in bipolar disorder
Table 5 Total Diagnosed Prevalent Cases of Bipolar Depression in the 7MM (2017–2030)
Table 6 Total Diagnosed Prevalent Cases of Bipolar Depression in the United States (2017–2030)
Table 7 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the United States (2017–2030)
Table 8 Severity-specific Diagnosed Prevalent cases of Bipolar Depression in the US (2017–2030)
Table 9 Total Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)
Table 10 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)
Table 11 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Germany (2017–2030)
Table 12 Total Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)
Table 13 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)
Table 14 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in France (2017–2030)
Table 15 Total Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)
Table 16 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)
Table 17 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Italy (2017–2030)
Table 18 Total Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)
Table 19 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)
Table 20 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Spain (2017–2030)
Table 21 Total Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)
Table 22 Type-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)
Table 23 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in the UK (2017–2030)
Table 24 Total Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)
Table 25 Total Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)
Table 26 Severity-specific Diagnosed Prevalent Cases of Bipolar Depression in Japan (2017–2030)
Table 27 Agents approved by the US FDA for acute bipolar mania, bipolar depression, and maintenance
Table 28 Categories of evidence (CE) and grade of recommendation (RG) for pharmacological and physical treatments used in acute Bipolar I depression (in alphabetical order within one category of evidence)
Table 29 Overall Recommendation Grades for long-term treatment
Table 30 Traditional evidence categories
Table 31 Vraylar (Cariprazine), Clinical Trial Description, 2020
Table 32 Vraylar (Cariprazine), Clinical Trial Description, 2020, Continued
Table 33 Latuda (Lurasidone Hydrochloride), Clinical Trial Description, 2020
Table 34 Latuda (Lurasidone Hydrochloride), Clinical Trial Description, 2020, Continued
Table 35 Key-Cross of Emerging Therapies
Table 36 Abilify (Aripiprazole), Clinical Trial Description, 2020
Table 37 Lumateperone (ITI-007), Patent Details
Table 38 Lumateperone (ITI-007), Clinical Trial Description, 2020
Table 39 NRX-100/NRX-101, Clinical Trial Description, 2020
Table 40 Psilocybin, Clinical Trial Description, 2020
Table 41 SAGE-217, Clinical Trial Description, 2020
Table 42 SEP-4199, Clinical Trial Description, 2020
Table 43 ILT101, Clinical Trial Description, 2020
Table 44 Falkieri (Esketamine), Clinical Trial Description, 2020
Table 45 Market Assumptions for Vraylar/Reagila
Table 46 Market Assumptions for Abilify
Table 47 Market Assumptions for Lumateperone/ITI-007
Table 48 Market Assumptions for NRX-100/NRX-101
Table 49 Market Assumptions for Zuranolone
Table 50 Market Assumptions for SEP-4199
Table 51 Market Assumptions for Falkieri
Table 52 Market Size of Bipolar Depression in the 7MM in USD Million (2017–2030)
Table 53 Market Size of Bipolar Depression by therapies in the 7MM, in USD Million (2017–2030)
Table 54 The US Market Size of Bipolar Depression in USD Million (2017–2030)
Table 55 Market Size of Bipolar Depression by therapies in the US, in USD Million (2017–2030)
Table 56 Germany Market Size of Bipolar Depression in USD Million (2017–2030)
Table 57 Market Size of Bipolar Depression by therapies in Germany, in USD Million (2017–2030)
Table 58 France Market Size of Bipolar Depression in USD Million (2017–2030)
Table 59 Market Size of Bipolar Depression by therapies in France, in USD Million (2017–2030)
Table 60 Italy Market Size of Bipolar Depression in USD Million (2017–2030)
Table 61 Market Size of Bipolar Depression by therapies in Italy, in USD Million (2017–2030)
Table 62 Spain Market Size of Bipolar Depression in USD Million (2017–2030)
Table 63 Market Size of Bipolar Depression by therapies in Spain, in USD Million (2017–2030)
Table 64 The UK Market Size of Bipolar Depression in USD Million (2017–2030)
Table 65 Market Size of Bipolar Depression by therapies in the UK, in USD Million (2017–2030)
Table 66 Japan Market Size of Bipolar Depression in USD Million (2017–2030)
Table 67 Market Size of Bipolar Depression by therapies in Japan, in USD Million (2017–2030)